ReviewProbiotics and antimicrobial proteins2026
Extracellular Vesicles from Lactic Acid Bacteria: Emerging Postbiotic Effectors in Host-Microbe Crosstalk.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article addresses extracellular vesicles derived from lactic acid bacteria (LAB-EVs), which have become fundamental mediators of host-microbe communication, yielding new insights about the molecular mechanisms underlying probiotic and postbiotic activity. The review integrates current evidence on the biogenesis, structural characteristics, and functional roles of LAB-EVs, stressing their capacity to transport bioactive cargos - including proteins, nucleic acids, and metabolites - to host cells. We highlight how LAB-EVs interact with the intestinal epithelial barrier, modulate innate and adaptive immune responses, and contribute to the maintenance of mucosal homeostasis. Particular attention is given to signaling pathways mediated by pattern recognition receptors, macrophage polarization, and the regulation of tight junction proteins, which collectively sustain barrier integrity and immune tolerance. Furthermore, we discuss the therapeutic implications of LAB-EVs in inflammatory bowel disease, epithelial repair, and systemic tissue regeneration. Despite these promising findings, significant obstacles remain in standardizing isolation methods, characterizing vesicle heterogeneity, and developing regulatory systems for clinical translation. Conquering these technical and safety barriers will be essential to consolidate LAB-EVs as safe and effective postbiotic tools in microbiome-based therapies. This review provides a discerning perspective on the current state of LAB-EVs research and describes future directions for their use in human health.
Indexed as
Identifiers
42776412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.